Psychosocial and Glycemic Benefits for Insulin-Using Adults With Type 2 Diabetes After Six Months of Pump Therapy: A Quasi-Experimental Approach
Authors' conclusion
The introduction of CSII (Omnipod DASH) in T2D adults can contribute to significant psychosocial, glycemic, and behavioral benefits, indicating that broader use of CSII in the T2D population may be of value.
Study context
- Population
- Adults with T2D on multiple daily injections (MDI) interested in starting Omnipod DASH220 completed 6-month follow-up
- Participants
- 458 adults
- Exposure
- Continuous subcutaneous insulin infusion (CSII) vs continued MDI
- CSIIn = 176
- MDIn = 44reference
- Outcome
- Psychosocial, glycemic and behavioral changes
- Follow-up
- Six months
Methodological detailslatent change score approach
- Latent change score approach
Main finding
As reported in the abstract
Psychosocial metrics
- CSII users reported greater gains than MDI users on all major psychosocial metrics
- CSII vs MDI: P < 0.001
- CSII vs MDI: P < 0.001
- CSII vs MDI: P = 0.003
- CSII vs MDI: P < 0.001
Observational data: associations, not effects.
Further findings
| Outcome | P value |
|---|---|
| HbA1c decline · six monthsLarger decline with CSII | P < 0.05 |
| Missed mealtime boluses · six monthsGreater decline with CSII | P < 0.001 |
| Days of perceived overeating · six monthsGreater decline with CSII | P = 0.001 |
Original publication
Psychosocial and Glycemic Benefits for Insulin-Using Adults With Type 2 Diabetes After Six Months of Pump Therapy: A Quasi-Experimental Approach. J Diabetes Sci Technol. Published 4 September 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →